Diclofenac Sodium Topical Solution Recalled Due to Manufacturing Quality Deviations
Preferred Pharmaceuticals, Inc. is recalling Diclofenac Sodium Topical Solution because the manufacturing firm discontinued its stability study program, a CGMP violation. All products within their expiration dates are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall without reported hospitalizations, injuries, or illnesses. The recall is precautionary in nature, triggered by manufacturing process deviations and discontinued stability studies rather than confirmed product defects or actual harm. Per the severity rubric, this qualifies as Moderate (Score 2).
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Diclofenac Sodium Topical Solution 1.5% w/w, a generic version of Pennsaid, supplied in 150 ml bottles. The recall affects 528 bottles distributed nationwide. The product is a prescription-only topical anti-inflammatory solution.
The recall was initiated because the manufacturing firm is discontinuing its stability study program, which violates Current Good Manufacturing Practice (CGMP) requirements. Stability studies are required to verify that a pharmaceutical product maintains its quality, strength, and purity throughout its shelf life. All products currently within their expiration dates are included in this recall.
Patients currently taking this medication should contact their prescribing healthcare provider or pharmacist to discuss this recall and explore alternative treatment options.
The recalled product
- Product
- Diclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid, 150 ml bottle, Rx Only, Mfg: Sola Pharmaceutical, Preferred Pharmaceuticals, Inc., The Physicians Solutions, NDC 68788-7918-01
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Topical Anti-inflammatory
- Affected units
- 528
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lots: E1220B
- Exp.: 01/31/2023
- F0220M
- Exp.: 3/31/2023
- F2320A
- F3020M
- G0920Q
- C0821M
- Exp.: 1/31/2024
- J1920
- Exp.: 5/31/2023
- E2421j
- Exp.: 4/30/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09